AU2021400738A1 - Long acting glucagon like polypeptide-1 (glp-1) receptor agonists and methods of use - Google Patents

Long acting glucagon like polypeptide-1 (glp-1) receptor agonists and methods of use Download PDF

Info

Publication number
AU2021400738A1
AU2021400738A1 AU2021400738A AU2021400738A AU2021400738A1 AU 2021400738 A1 AU2021400738 A1 AU 2021400738A1 AU 2021400738 A AU2021400738 A AU 2021400738A AU 2021400738 A AU2021400738 A AU 2021400738A AU 2021400738 A1 AU2021400738 A1 AU 2021400738A1
Authority
AU
Australia
Prior art keywords
glp
polypeptide
methods
receptor agonists
long acting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021400738A
Other languages
English (en)
Inventor
William Blackwell
Mark Paulik
Ved P. SRIVASTAVA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
I2O Therapeutics Inc
Original Assignee
I2O Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by I2O Therapeutics Inc filed Critical I2O Therapeutics Inc
Publication of AU2021400738A1 publication Critical patent/AU2021400738A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2021400738A 2020-12-17 2021-12-16 Long acting glucagon like polypeptide-1 (glp-1) receptor agonists and methods of use Pending AU2021400738A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063126736P 2020-12-17 2020-12-17
US63/126,736 2020-12-17
PCT/US2021/063920 WO2022133148A1 (en) 2020-12-17 2021-12-16 Long acting glucagon like polypeptide-1 (glp-1) receptor agonists and methods of use

Publications (1)

Publication Number Publication Date
AU2021400738A1 true AU2021400738A1 (en) 2023-07-13

Family

ID=80123475

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021400738A Pending AU2021400738A1 (en) 2020-12-17 2021-12-16 Long acting glucagon like polypeptide-1 (glp-1) receptor agonists and methods of use

Country Status (12)

Country Link
US (2) US12084485B2 (https=)
EP (1) EP4263587A1 (https=)
JP (1) JP2024502740A (https=)
KR (1) KR20230156689A (https=)
CN (1) CN116917311A (https=)
AR (1) AR124395A1 (https=)
AU (1) AU2021400738A1 (https=)
CA (1) CA3202389A1 (https=)
IL (1) IL303686A (https=)
MX (1) MX2023007224A (https=)
TW (1) TW202237628A (https=)
WO (1) WO2022133148A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
MX2024003236A (es) 2021-09-15 2024-06-19 Viking Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos.
AU2024218747A1 (en) * 2023-02-10 2025-08-28 Hangzhou Sciwind Biosciences Co., Ltd. Polypeptide and derivative thereof, composition, and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100256056A1 (en) 2007-09-07 2010-10-07 Zheng Xin Dong Analogues of exendin-4 and exendin-3
SMT201700583T1 (it) 2009-09-28 2018-01-11 Intarcia Therapeutics Inc Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
JP6165168B2 (ja) * 2011-12-22 2017-07-19 ファイザー・インク 抗糖尿病化合物
UA116217C2 (uk) * 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
RU2760007C2 (ru) * 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
AU2017277594A1 (en) * 2016-06-09 2019-02-07 Medimmune Limited Protease-resistant mono-lipidated peptides
CN111333714A (zh) 2020-03-05 2020-06-26 成都奥达生物科技有限公司 一种长效glp-1化合物

Also Published As

Publication number Publication date
JP2024502740A (ja) 2024-01-23
AR124395A1 (es) 2023-03-22
MX2023007224A (es) 2023-09-05
CA3202389A1 (en) 2022-06-23
WO2022133148A1 (en) 2022-06-23
IL303686A (en) 2023-08-01
US20250034225A1 (en) 2025-01-30
TW202237628A (zh) 2022-10-01
KR20230156689A (ko) 2023-11-14
US12084485B2 (en) 2024-09-10
US20230063420A1 (en) 2023-03-02
CN116917311A (zh) 2023-10-20
EP4263587A1 (en) 2023-10-25

Similar Documents

Publication Publication Date Title
AU2021400738A1 (en) Long acting glucagon like polypeptide-1 (glp-1) receptor agonists and methods of use
EP4227299A4 (en) GLP-1 RECEPTOR AGONIST, BENZIMIDAZOLONE AND ITS USE
HUE071004T2 (hu) GLP-1 receptor agonista és alkalmazása
EP4212527A4 (en) GLP-1R RECEPTOR AGONIST COMPOUND AND USE THEREOF
IL304521A (en) GPCR receptor agonists, pharmaceutical preparations containing them and methods of using them
IL277288A (en) Interleukin-2 / interleukin-2 receptor alpha fusion proteins and methods of use
AU2003273300A1 (en) Modified glp-1 receptor agonists and their pharmacological methods of use
AU2024250528A1 (en) Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof
PL368760A1 (en) Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
EP4095149A4 (en) TRIPLE AGONIST FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR, GLUCAGON RECEPTOR, AND GASTRIC INHIBITOR POLYPEPTIDE RECEPTOR
HK40102671A (en) Long acting glucagon like polypeptide-1 (glp-1) receptor agonists and methods of use
EP4180452A4 (en) FUSION PROTEIN WITH GLUCAGON-LIKE PEPTIDE-1 AND INTERLEUKIN-1 RECEPTOR ANTAGONIST AND USE THEREOF
EP4140984A4 (en) GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONIST AND USE THEREOF
HK40089190A (en) Alpha1a-adrenergic receptor agonists and methods of use
HK40099221A (en) Glp-1 receptor agonist and composition and use thereof
HK40089159A (en) Long acting glucagon receptor selective peptides and methods of use
HK40111760A (en) Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof
HK40113396A (en) Pharmaceutical composition of glp-1 and gip receptor dual agonist and use thereof
IL315798A (en) Alpha 1A-adrenergic receptor agonists and methods of use
CA3279765A1 (en) Il12 receptor agonists and methods of use thereof
HK40122676A (en) Salt-type glp-1 receptor agonist, crystal form thereof, preparation method therefor, pharmaceutical composition thereof, and use thereof
CA3301356A1 (en) Toll-like receptor agonists and use thereof
HK40087533A (en) Crf receptor antagonists and methods of use
HK40079209A (en) Glp receptor agonists
HK40102220A (en) Co-agonists of the glp-1 and amylin receptors